Trial Profile
Phase Ⅱ, Single-arm Study of Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects [SUKSES-N4]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-N4
- 29 Dec 2023 Status changed from active, no longer recruiting to completed.
- 06 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Jun 2020 Planned End Date changed from 31 May 2022 to 31 Dec 2023.